MITCHELL DEAN J 4

What Happened
Dean J. Mitchell, a director of Theravance Biopharma (TBPH), was granted two awards on 2026-06-12: 6,009 shares reported as an acquisition at $0 and a derivative award (an option) covering 13,398 shares also reported at $0. The filing lists the reported acquisition values as $0; the derivative is an option that can convert into shares upon vesting and exercise. Combined, the awards cover 19,407 shares.

Key Details

• Transaction date: 2026-06-12; Form 4 filed 2026-06-16 (appears to be filed later than the typical 2-business-day Form 4 deadline).
• Grants reported: 6,009 shares (A) at $0; 13,398 derivative shares (A) at $0. Reported total purchase value: $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnote (F1): the option vests 1/12th per month after the grant date; any remaining unvested shares vest on the date of the next annual shareholders’ meeting, provided continuous service.
• No indication in the filing that shares were sold immediately (not a cashless exercise or sale).

Context
These entries are award/grant transactions (code A). The 13,398-share item is a stock option (derivative) subject to vesting per the footnote—options must vest and be exercised before they become common shares. Awards and option grants are routine compensation for directors and do not by themselves indicate a buy or sell decision in the open market.